The 2024 Avoca State of the Industry Report

For more than 20 years, Avoca, a WCG company, has surveyed the industry to gain an understanding of key trends affecting clinical development, in order to provide insights that can strengthen relationships and enhance R&D quality and productivity.

With the expectation of revised guidance under ICH E6 (R3) to be finalized in the fall of 2024, the topic of this year’s industry survey focused on understanding current awareness of proposed changes and gauging perceived impacts – both positive and negative – among stakeholders in clinical trial development and execution. The goals of this research were to assess current levels of awareness and engagement with proposed ICH E6 (R3) changes, understand reaction to select excerpts of the proposed guidance, and to identify information and support needs that will foster collaboration and implementation. Download now to learn more.

Download the Document

    * denotes a required field

    Please fill out the information below. If you are already registered, and this information will be filled out for you.


  • Please enter your first and last name.

  • Please enter the name of the company or institution you work at.

  • Please enter your mailing address.

  • Please enter the phone number you would like to be contacted at.

  • Please enter the e-mail address you would like to be contacted at.

  • By submitting this form, you consent to Pharmaceutical Outsourcing storing your email address and contact information and transmitting your contact information to the content sponsor. You may request to be removed at any time.